| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Amanizumab (3-243 nM) binds with high affinity to recombinant human ON/4R tau protein, with an equilibrium dissociation constant of 3.88E-08 M [1]. Amanizumab (0.02-12.5 μM; 1.5 h) specifically targets the PRQEF epitopes (amino acids 4-8) of tau 2-18, where amino acids 6 (glutamine) and 7 (glutamate) are crucial for binding [1]. Amanizumab (1 μM; 16 h) partially protects SH-SY5Y human neuroblastoma cells from tau oligomer-mediated cytotoxicity [1].
|
|---|---|
| ln Vivo |
Armanezumab (2 μg; intracranial injection; single dose) was administered for 5 days and reduced total tau protein and multiple phosphorylated pathological tau proteins in the brains of THY-Tau22 tau transgenic mice [1].
|
| Cell Assay |
Cytotoxicity assay [1]
Cell Types: SH-SY5Y human neuroblastoma cells Tested Concentrations: 1 μM (pre-incubated with Armanezumab and 0.5 μM tau oligomers) Incubation Duration: 16 hours (cells incubated with oligomer-Armanezumab mixture) Experimental Results: The survival rate of SH-SY5Y cells was restored to 89% compared with the 36% survival rate of cells treated with tau oligomers alone, protecting cells from tau oligomer-mediated cytotoxicity. |
| Animal Protocol |
Animal/Disease Models:THY-Tau22 tau transgenic mice (6 months old) [1]
Doses: 2 μg Route of Administration: Intracranial injection (hippocampus and cortex); single dose Experimental Results: Compared with the control hemisphere injected with IgG on the contralateral side, the ipsilateral hemisphere showed reduced levels of total tau protein (HT7 staining) and phosphorylated tau protein (including pThr212, pSer214, pSer396/pSer404 (PHF1 staining), pThr212/pSer214 (AT100 staining), pThr231 (AT180 staining), and pSer202/pThr205 (AT8 staining)). Neuronal integrity at the injection site was confirmed by anti-NeuN staining. |
| References |
| Appearance |
Typically exists as solids at room temperature
|
|---|---|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
